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Peptides containing various α,α-disubstituted α-amino acids, such as α-
aminoisobutyric acid (Aib), 1-aminocyclopentane-1-carboxylic acid, α-
methylphenylalanine, and 3-aminotetrahydro-2H-pyran-3-carboxylic acid have 
been synthesized from the N- to the C-terminus by means of the 
‘azirine/oxazolone method’ under solid-phase conditions. In this convenient 
method for the synthesis of sterically demanding peptides on solid-phase, 2H-
azirin-3-amines are used to introduce the α,α-disubstituted α-amino acids without 
the need of additional reagents. Furthermore, the synthesis of poly-Aib sequences 
has been explored. 
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1. Introduction. – Due to the restrictions in their conformational freedom, 
α,α-disubstituted α-amino acid containing peptides form stabilized secondary 
structures, such as β-turns and helices [1–4]. One useful method for the 
introduction of α,α-disubstituted α-amino acids into peptides is the 
‘azirine/oxazolone method’ [5–7]. Thus, the reaction of 2H-azirin-3-amines, e.g. 
the Aib synthon 1, with an amino or peptide acid proceeds smoothly and in high 
yield. The terminal amide bond of the resulting peptide amide can be hydrolyzed 
selectively to give the extended peptide acid. In solution-phase chemistry, the 
‘azirine/oxazolone method’ has proven to be successful for the introduction of a 
multitude of sterically demanding α,α-disubstituted α-amino acids into peptides, 
and it has found application in the synthesis of some antibiotic peptaibols or 
segments thereof [8–15]. 
Since solid-phase synthesis offers rapid access to peptides without the need for 
the isolation of the sometimes cumbersome peptide acid intermediates, we 




In this convenient method for the synthesis of sterically demanding peptides on 
solid-phase, the first amino acid was attached through a carbamate linker to a [4-
(hydroxymethyl)phenyl]acetamidomethyl (PAM) polystyrene resin (2). 
Deprotection of the tBu ester 3 with TFA afforded resin 4, which was treated with 
a solution of N,2,2-trimethyl-N-phenyl-2H-azirin-3-amine (1). Unconsumed 1 
could easily be recovered and reused. Selective hydrolysis of the terminal amide 
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with 3 M HCl in THF/H2O afforded peptide acid resin 6. Further extension of the 
peptide chain could be achieved either with a tBu ester protected amino acid and a 
coupling reagent, e.g. PyBOP, or with 1. Cleavage from the resin was achieved 
with HBr (33%) in acetic acid to give the tripeptide 7. 
It was of interest to ascertain if this method is restricted to the α-
aminoisobutyric acid (Aib) synthon 1, or if it can be extended to other 2H-azirin-
3-amines. Herein we report the use of the 1-aminocyclopentane-1-carboxylic acid 
(Acp) synthon 8, the 3-aminotetrahydro-2H-pyran-3-carboxylic acid (Thp) 
synthon 9, and the α-methylphenylalanine (Phe(2Me)) synthon 10 in peptide 
synthesis using the ‘azirine/oxazolone method’ under solid-phase conditions. 
Furthermore, a limitation of the method in the synthesis of poly-Aib sequences is 
revealed. 
 
Formula collection 1 
 
2. Results and Discussion. – In analogy to the model peptide H–Ala–Aib–
Phe–OH, which had been used to establish the viability of the ‘azirine/oxazolone 
method’ under solid-phase conditions, the tripeptides H–Ala–Acp–Phe–OH (11a) 
and H–Ala–Thp–Phe–OH (11b) were synthesized on solid-phase in 37% and 38% 
yield (after prep. HPLC, based on resin loading), respectively (see Scheme 1; 
instead of 1, the Acp and Thp synthons 8 and 9 were used; Table 1). Both α,α-
disubstituted residues were introduced by the ‘azirine/oxazolone method’, and Phe 
with PyBOP as the coupling reagent. 
 
page 5 / 39 
Formula collection 2 
 
When (S)-1-[(S)-2-benzy1-2-methy1-2H-azirin-3-y1]-2-(1-methoxy-1-
methylethyl)pyrrolidine (12) was used as an optically pure Phe(2Me) synthon, the 
syntheses of H–Ala–Phe(2Me)–Phe–OH and H–Ala–Phe(2Me)–Leu–OH failed, 
although this 2H-azirin-3-amine has been used successfully in solution-phase 
chemistry. N-Methyl-N-phenyl-2H-azirin-3-amines belong to the most reactive 
2H-azirin-3-amines. Therefore, the racemic Phe(2Me)-synthon 10 was used in a 
second, successful attempt to synthesize the tripeptide H–Ala–Phe(2Me)–Leu–OH 
(13) as a mixture of two diastereoisomers. The diastereoisomers (S,S,S)-13 and 
(S,R,S)-13 were separated by means of preparative HPLC, which gave the two 
isomers in a 1:1 ratio in 49% yield. 
X-ray crystallography would have allowed the configuration of the C(α)-center 
of the Phe(2Me) residue to be determined, but all attempts to crystallize at least 
one of the two diastereoisomeric tripeptides 13 failed. Therefore, (S,S,S)-13 and 
(S,R,S)-13 were derivatized with 4-bromobenzoyl chloride (Scheme 2). Crystals, 
suitable for an X-ray crystal-structure determination were obtained from (S,S,S)-
14 (Fig. 1) and the absolute configuration of the molecule was determined 
independently by the diffraction experiment. This confirmed the (S)-
configurations of the alanine and leucine residues and revealed the (S)-
configuration of the Phe(2Me) residue. The knowledge of the absolute 
configuration of (S,S,S)-14 allowed the absolute configurations of the primarily 
isolated tripeptides (S,S,S)-13 and (S,R,S)-13 to be assigned. 
 




The asymmetric unit in the structure of (S,S,S)-14 contains two symmetry-
independent peptide and two MeOH molecules. The two peptide molecules have 
very similar conformations and differ primarily in the orientation of the plane of 
the bromophenyl ring. Each peptide molecule is involved in one intramolecular 
and four intermolecular H-bonds. The amide group closest to the carboxy group in 
each peptide molecule forms an intramolecular H-bond with the amide O-atom 
adjacent to the bromophenyl moiety thereby stabilizing a β-turn. Each of these 
interactions has a graph set motif [18] of S(10). The OH-group in each peptide 
molecule forms an intermolecular H-bond with the O-atom of a neighbouring 
MeOH molecule. In turn, each of these MeOH molecules forms an intermolecular 
H-bond to one of the symmetry-independent peptide molecules. These 
interactions link the peptide and MeOH molecules alternately into extended 
chains which run parallel to the [0 1 0] direction in the sequence 
···peptideA···MeOH2···peptideB···MeOH1···peptideA···. The quaternary graph 
set motif that describes this sequence is C4,4(26). The amide group closest to the 
bromophenyl moiety in peptide molecule A forms an intermolecular H-bond with 
the carboxylate carbonyl O-atom of a neighbouring molecule B. In turn, molecule 
B interacts in an identical fashion with another molecule A. These interactions 
link peptide molecules A and B alternately into extended chains, which run 
parallel to the [0 -1 1] direction and can be described by a binary graph set motif 
of C2,2(22). The central amide group in peptide molecule A forms an 
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intermolecular H-bond with the carbonyl O-atom of the amide group closest to the 
carboxylic acid end of a neighbouring molecule A. This interaction links the 
peptide molecules A into centrosymmetric dimers and can be described by a graph 
set motif of R2,2(10). The peptide molecules B display identical interactions that 
also link the molecules into centrosymmetric dimers. The combination of all 
intermolecular H-bonding interactions links the peptide and MeOH molecules into 
extended two-dimensional networks which lie parallel to the (1 0 0) plane. 
Some longer model peptides containing up to three α,α-disubstituted residues 
were synthesized successfully on solid-phase (Table 1). The pentapeptides H–
Val–Thp–Gly–Acp–Ala–OH (15) and H–Ala–Thp–Val–Thp–Phe–OH (16) were 
obtained in 23% and 16% yield, respectively. All α,α-disubstituted residues were 
introduced by the ‘azirine/oxazolne method’, while the couplings of the other 
amino acids were introduced by using PyBOP as the coupling reagent. The 1H-
NMR spectrum of 15 showed partial doubling of the signals. The contribution of 
the minor signals is ca. 20%. Unexpectedly, while increasing the temperature in 
the NMR experiment, the chemical shifts of the minor and major NH signals did 
not coalesce or converge. The convergence of the NH signals with increasing 
temperature would have been strong evidence for the existence of conformers and 
not diastereoisomers. To rule out the presence of diastereoisomers, however, an 
amino acid analysis was performed [19]: in order to determine the extent of 
racemization/epimerization of the C(α) center(s), the pentapeptide was 
hydrolyzed and the amino acids were analyzed by capillary gas chromatography 
with enantiomer labelling. The results showed that alanine and valine had 
racemized by 0.4% and 0.8%, respectively. Thus, the doubling of the  signals in 
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the 1H-NMR was caused by different conformers and not by diastereoisomers. 
Furthermore, this analysis shows that, although the peptide was synthesized from 





The heptapeptides H–Ala–Aib–Val–Acp–Gly–Thp–Leu (17) and H–Ala–Aib–
Val–Acp–Phe–Thp–Leu (18) were synthesized analogously on solid-phase with 
yields of 21% and 13%, respectively. The two peptides only differ in one amino 
acid (Gly(4) → Phe(4)). While the coupling of the α,α-disubstituted α-amino acid 
is a difficult step (which has been solved by using 2H-azirin-3-amines), the 
following coupling can be difficult too, so we assume that this might be the reason 
for the noticeably lower yield of 18 compared with 17. 
Peptides containing α,α-disubstituted α-amino acids stabilize or even promote 
secondary structures, such as helices or β-turns.  Therefore, poly-Aib motifs with 
an accumulation of helix-stabilizing residues are of some interest. The repeated 
coupling of 2H-azirin-3-amines in solution is an efficient method for the 
preparation of this type of sterically highly congested oligopeptides [20] [21]. The 
tripeptide H–(Aib)3–OH (19) was synthesized using the ‘azirine/oxazolone 
method’ on solid-phase in 33% yield (Table 2), but the preparation of H–(Aib)4–
OH failed. A similar result was obtained in the extension from H–Ala–(Aib)2–OH 
(20) to H–Ala–(Aib)3–OH (21). While 20 could be prepared in 41% yield, 21 was 
obtained in a conspicuously lower yield (ca. 12%, not pure; additionally, 35% of 
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20 were obtained). The introduction of the fourth amino acid in H–Ala–Aib–Aib–
Val–OH with conventional coupling by using PyBOP as the coupling reagent was 
also in vain. All attempts to improve the introduction of the fourth amino acid, 
such as performing the reaction in different solvents (CH2Cl2, THF, DMF, PhMe, 
H2O), raising the temperature to 50° or using a Tentagel resin were not effective. 
Since the most probable reason for the failure is aggregation, we also performed 
the reaction by using the ‘magic mixture’ [22] (DCM/DMF/NMP (1:1:1), triton 
X-100, ethylenecarbonate (2 M)) and in CHCl3/hexafluoroisopropanol (1:1), but 




A slight improvement was observed if proteinogenic α-amino acids were 
introduced prior to the poly-Aib motif, e.g., H–Ala–Val–Aib–Aib–Aib–OH (22) 
was prepared in 16% yield. Furthermore, the poly-Aib containing peptides H–
Ala–Val–Phe–Aib–Aib–Leu–OH (23) and H–Ala–Val–Phe–Aib–Aib– Aib–Leu–
OH (24) were synthesized, although in low yield (6% and 9%, respectively). All 
Aib residues were introduced by the ‘azirine/oxazolone method’, while all other 
amino acids were introduced by using PyBOP as the coupling reagent. 
 
3. Conclusions. – Peptide synthesis using the ‘azirine/oxazolone method’ on 
solid-phase was carried out from the N- to the C-terminus. 2H-Azirin-3-amines 
were used to introduce α,α-disubstituted α-amino acids into the peptides without 
the need for further reagents. It was shown that the method is not limited to the 
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Aib synthon 1, and it was extended successfully to the 1-aminocyclopentane-1-
carboxylic acid (Acp) synthon 8, the 3-aminotetrahydro-2H-pyran-3-carboxylic 
acid (Thp) synthon 9 and the α-methylphenylalanine (Phe(2Me)) synthon 10. 
Peptides with up to seven residues, of which three are α,α-disubstituted α-amino 
acids, have been prepared. In contrast, the synthesis of peptides containing the 
poly-Aib motif was not successful, most probably due to aggregation. 
 
We thank Dr. Daniel Obrecht, Polyphor Ltd, Allschwil (Switzerland) for 
continous advice and valuable discussions, as well as the analytical sections of our 
institute for 2D-NMR measurements and mass spectra. Financial support of the 
Swiss National Science Foundation and F. Hoffmann-La Roche AG, Basel is 
gratefully acknowledged. 
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EXPERIMENTAL PART 
 
1. General. See [16], except analytic HPLC-MS: The system consists of a 
Rheos 2000 pump, a Rheos CPS-LC degasser (Flux Instruments, Basel, 
Switzerland) and a Thermo Finnigan Surveyor photo-diode array detector 
(Thermo Finnigan, San Jose, CA, USA). The HPLC-system is equipped with a 
HTS PAL autosampler (CTC Analytics, Zwingen, Switzerland) and connected to a 
Thermo Finnigan MSQ linear quadrupole instrument. Method A: Interchim 
Uptisphere C18-NEC, 120 Å, 3 µm, 50 × 2.0 mm column (Interchim, Montluçon, 
France); eluents: A = H2O, B = MeCN, C = HCOOH (1%) in H2O; flow rate: 0.2 
ml/min, gradient (A:B:C): 0.0–10.0 min: 85:5:10–75:15:10. Method B: Interchim 
Uptisphere C18-ODB, 120 Å, 3 µm, 50 × 2.0 mm column; eluents: A = H2O, B = 
MeCN, C = HCOOH (1%) in H2O; flow rate: 0.2 ml/min, gradient (A:B:C): 0.0–
15.0 min: 87:3:10–40:50:10. N,2,2-Trimethyl-N-phenyl-2H-azirin-3-amine (1), N-
methyl-N-phenyl-1-azaspiro[2.4]hept-1-en-2-amine (8), N-methyl-N-phenyl-6-
oxa-1-azaspiro[2.5]oct-1-en-2-amine (9), and 2-benzyl-N,2-dimethyl-N-phenyl-
2H-azirin-3-amine (10) were synthesized by Villalgordo and Heimgartner’s 
method [23–25]. (S)-1-[(S)-2-benzy1-2-methy1-2H-azirin-3-y1]-2-(1-methoxy-1-
methylethyl)pyrrolidine (12) was synthesized according to [26]. In the NMR data, 
the integer n in Xaan corresponds to the position of the amino acid within the 
peptide, but is only given if the amino acid was present more than once in the 
peptide and if the NMR signal could be assigned unambigously. In some 1H-NMR 
spectra, the broad COOH signal could not be detected. In the 1H- and 13C-NMR 
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spectra of 15, the descriptor (w) means the weaker, (s) the stronger signal of the 
two conformers observed. 
2. Abbreviations. Aib: α-aminoisobutyric acid; CC: column chromatography; 
Acp: 1-aminocyclopentane-1-carboxylic acid; DCM: dichloromethane; DIPEA: 
N,N-diisopropylethylamine; HOBt: 1-hydroxybenzotriazole; PAM: [4-
(hydroxymethyl)phenyl]acetamidomethyl; Phe(2Me): 2-amino-2-methyl-3-
phenylpropanoic acid; PyBOP: (1H-benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate; Thp: 3-aminotetrahydro-
2H-pyran-3-carboxylic acid; TIPS: triisopropylsilane. 
3. General Procedures (GP1–GP6). GP1: Attachment of the First Amino Acid. 
All manipulations were carried out under N2. PAM resin was swollen in THF. 
After filtration, a soln. of COCl2 in toluene (1.9 M, 10 equiv.) and THF (ca. 2.5 
ml/1 g resin) were added to the resin, which was agitated at r.t. for 2 h, then 
washed with THF (2×) and DCM (2×). In a separate vial, H–Xaa–OtBu · HCl (4 
equiv.) was dissolved in DIPEA (8 equiv.) and DCM (conc. of H–Xaa–OtBu · 
HCl = 0.2 M). This mixture was added to the resin, and any ammonium salt that 
occured was removed by filtration. The resin was agitated at r.t. overnight, then 
washed with DMF (3×) and DCM (3×). 
GP2: Removing the tBu Protecting Group. The resin was swollen in DCM. 
TFA in DCM (1×5 s, 25%; 1×30 min, 50%) and TIPS (5%, in each case) were 
added and the resin agitated at r.t. Afterwards, the resin was washed with DCM 
(3×), DMF (2×) and DCM (3×). 
GP3: Coupling with 2H-azirin-3-amines 1, 8, 9, 10. The resin was swollen in 
DCM. A soln. of 2H-azirin-3-amine (4 equiv.) in DCM (conc. of 2H-azirin-3-
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amine = 0.2 M) was added and the resin agitated at r.t. overnight, then washed 
with DCM (3×). Unconsumed 2H-azirin-3-amine can easily be recovered. 
GP4: Hydrolysis of the Terminal Amide. The resin was swollen in THF. Aq. 
HCl (ca. 3-4 ml/200 mg resin, 3 M in THF/H2O, prepared from conc. HCl and 
THF) was added and the resin agitated at r.t. overnight, then washed with THF 
(3×), DMF (3×) and DCM (3×). 
GP5: Coupling with H–Xaa–OtBu · HCl. The resin was swollen in DMF. 
HOBt (6 equiv.) in DMF, PyBOP (4 equiv.) in DMF, H–Xaa–OtBu · HCl (4 
equiv.) in DMF and DIPEA (12 equiv.) was added (conc. of H–Xaa–OtBu . HCl = 
0.2 M), and the resin agitated at r.t. overnight, then washed with DMF (3×) and 
DCM (3×). 
GP6: Cleavage. The resin was swollen in DCM. HBr in AcOH (33%, 1 ml/100 
mg resin), two drops of H2O were added and the resin agitated for 6 h. The resin 
was separated by filtration and washed with AcOH/DCM (1:1, 3×) and 
MeCN/DCM (1:1, 3×). The solvents were evaporated under reduced pressure and 
the crude product was purified by means of HPLC. The purified product was 
lyophilized. 
4. Synthesis of Peptides. 2(S)-[({[(2S)-Amino-1-
oxopropyl)amino]cyclopentyl}carbonyl)amino]-3-phenylpropanoic Acid (H–Ala–
Acp–Phe–OH; 11a). PAM resin (200 mg, 0.124 mmol) was treated as described 
in GP 1, 2, 3, 4, 5 and 6 to yield 11a (21.0 mg, 37%) as a colorless powder after 
prep. HPLC purification and lyophilization. HPLC-MS (method B): tR = 7.7 min, 
m/z = 348 (100, [M + H]+), 183 (76, [M – Phe]+), 155 (20, [M – Phe – CO]+). IR 
(KBr): 3397m, 3262s, 3076s, 2962m, 2876m, 1731s, 1664sh, 1647vs, 1561m, 
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1517s, 1490m, 1455m, 1442m, 1382w, 1331w, 1266m, 1238m, 1202vs, 1141s, 
1004w, 982w, 845w, 802w, 734w, 724w, 699w. 1H-NMR ((D6)DMSO, 600 MHz): 
12.84 (br. s, COOH); 8.53, 8.48 (2s, NH(Acp)); 8.06 (br. s, NH3(Ala)); 7.36 (d, J 
= 7.7, NH(Phe)); 7.27–7.17 (m, 5 arom. H); 4.44 (ddd, J = 7.7, 7.7, 5.6, 
CH(α)(Phe)); 3.82 (br. s, CH(α)(Ala)); 3.07 (dd, 2J = 13.8, J = 5.6, 1 H of 
CH2(Phe)); 2.94 (dd, 2J = 13.8, J = 7.7, 1 H of CH2(Phe)); 2.14–2.09 (m, 1 H of 4 
CH2(Acp)); 1.89–1.82 (m, 3 H of 4 CH2(Acp)); 1.60–1.59 (m, 4 H of 4 
CH2(Acp)); 1.33 (d, J = 7.0, Me(Ala)). 13C-NMR ((D6)DMSO, 150 MHz): 172.7 
(s, CO(Phe)); 172.2 (s, CO(Acp)); 169.3 (s, CO(Ala)); 137.4 (s, arom. C); 129.3, 
128.1, 126.4 (3d, 5 arom. CH); 66.4 (s, C(α)(Acp)); 53.4 (d, CH(α)(Phe)); 48.3 
(d, CH(α)(Ala)); 36.9 (t, CH2(Phe)); 36.3, 35.3, 23.7 (3t, 4 CH2(Acp)); 16.9 (q, 
Me(Ala)). ESI-MS: 370 (8, [M + Na]+), 348 (100, [M + H]+), 183 (13, [M – 
Phe]+), 151 (24). 
2(S)-[({4-[(2(S)-Amino-1-oxopropyl)amino]tetrahydro-2H-pyran-4-
yl}carbonyl)amino]-3-phenylpropanoic Acid (H–Ala–Thp–Phe–OH; 11b). PAM 
resin (200 mg, 0.124 mmol) was treated as described in GP 1, 2, 3, 4, 5 and 6 to 
yield 11b (22.5 mg, 38%) as a colorless powder after prep. HPLC purification and 
lyophilization. HPLC-MS (method B): tR = 6.1 min, m/z = 364 (100, [M + H]+), 
199 (58, [M – Phe]+). IR (KBr): 3425s, 3243s, 3061vs, 3033vs, 2875s, 2616w, 
1724vs, 1678vs, 1533vs, 1499s, 1455m, 1444m, 1429m, 1394m, 1356m, 1331w, 
1302m, 1261s, 1244s, 1202vs, 1141s, 1102s, 1029w, 1019w, 969w, 843w, 800w, 
723m, 701m. 1H-NMR ((D6)DMSO, 600 MHz): 12.79 (br. s, COOH); 8.43 (s, 
NH(Thp)); 8.06 (br. s, NH3(Ala)); 7.52 (d, J = 8.0, NH(Phe)); 7.28–7.51 (m, 5 
arom. H); 4.46 (ddd, J = 8.3, 8.0, 5.4, CH(α)(Phe)); 3.95 (q, J = 6.7, CH(α)(Ala)); 
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3.68–3.65, 3.59–3.59, 3.52–3.46 (3m, 2 CH2O(Thp)); 3.08 (dd, 2J = 13.8, J = 5.4, 
1 H of CH2(Phe)); 2.95 (dd, 2J = 13.8, J = 8.3, 1 H of CH2(Phe)); 1.99–1.94, 1.87–
1.76 (2m, 2 CH2CH2O(Thp)); 1.38 (d, J = 7.0, Me(Ala)). 13C-NMR ((D6)DMSO, 
150 MHz): 172.6 (s, CO(Phe)); 171.9 (s, CO(Thp)); 169.5 (s, CO(Ala)); 137.4 (s, 
arom. C); 129.3, 128.1, 126.4 (3d, 5 arom. CH); 62.6, 62.3 (2t, 2 CH2O(Thp)); 
57.0 (s, C(α)(Thp)); 53.3 (d, CH(α)(Phe)); 48.4 (d, CH(α)(Ala)); 36.9 (t, 
CH2(Phe)); 31.9, 31.3 (2t, 2 CH2CH2O(Thp)); 17.1 (q, Me(Ala)). ESI-MS: 364 
(100, [M + H]+). 
2(S)-({2(S)-[(2(S)-Amino-1-oxopropyl)amino]-2-benzyl-1-oxopropyl}amino)-
4-methylpentanoic Acid and 2(S)-({2(R)-[(2(S)-Amino-1-oxopropyl)amino]-2-
benzyl-1-oxopropyl}amino)-4-methylpentanoic Acid (H–Ala–Phe(2Me)–Leu–OH; 
(S,S,S)-13 and (S,R,S)-13). PAM resin (200 mg, 0.124 mmol) was treated as 
described in GP 1, 2, 3, 4, 5 and 6 to yield  (S,S,S)-13 and (S,R,S)-13 in a 1:1 ratio  
as colorless powders after prep. HPLC purification and lyophilization (29 mg, 
49% altogether). Data of (S,S,S)-13. HPLC-MS (method B): tR = 8.8 min, m/z = 
364 (100, [M + H]+). IR (KBr): 3045sh, 3281s, 3066s, 3033s, 2960s, 2874s, 
2623w, 1672vs, 1528vs, 1454m, 1388m, 1329w, 1268m, 1238m, 1202vs, 1141vs, 
1031w, 1004w, 969w, 928w, 879w, 838w, 800w, 740w, 722m, 706m. 1H-NMR 
((D6)DMSO, 600 MHz): ca. 9.5–8.0 (br. s, NH3(Ala)); 8.09 (s, NH(Phe(2Me))); 
7.82 (d, J = 8.2, NH(Leu)); 7.27–7.21, 7.12–7.11 (2m, 5 arom. H); 4.36–4.32 (m, 
CH(α)(Leu)); 3.81–3.80 (m, CH(α)(Ala)); 3.36, 3.18 (AB, J = 13.5, PhCH2); 
1.68–1.59 (m, CH(γ)(Leu), 1 H of CH2(Leu)); 1.52–1.41 (m, 1 H of CH2(Leu)); 
1.31 (s, Me(Phe(2Me))); 1.30 (d, J = 7.0, Me(Ala)); 0.88, 0.86 (2d, J = 6.5, 2 
Me(Leu)). 13C-NMR ((D6)DMSO, 150 MHz): 174.3 (s, CO(Leu)); 172.5 (s, 
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CO(Phe(2Me))); 169.4 (s, CO(Ala)); 136.8 (s, arom. C); 130.6, 127.8, 126.4 (3d, 
5 arom. CH); 59.6 (s, C(α)(Phe(2Me))); 50.5 (d, CH(α)(Leu)); 48.8 (d, 
CH(α)(Ala)); 40.1 (t, CH2(Leu)); 38.8 (t, PhCH2); 24.0 (d, CH(γ)(Leu)); 23.7 (q, 
Me(Phe(2Me))); 23.0, 21.4 (2q, 2 Me(Leu)); 17.1 (q, Me(Ala)). ESI-MS: 408 (12, 
[M – H + 2 Na]+), 386 (100, [M + Na]+), 364 (11, [M + H]+), 293 (7, [M – Ala + 
H]+), 233 (8, [M – Leu]+), 205 (23, [M – Leu – CO]+), 134 (28). 
Data of (S,R,S)-13. HPLC-MS (method B): tR = 9.7 min, m/z = 364 (100, [M + 
H]+). IR (KBr): 3291s, 3066s, 3034s, 2961s, 2875s, 2618w, 1720s, 1670vs, 
1525vs, 1468m, 1454m, 1387m, 1329w, 1269m, 1202vs, 1143vs, 1031w, 1004w, 
968w, 927w, 838w, 800w, 742w, 723m, 703m. 1H-NMR ((D6)DMSO, 600 MHz): 
8.11 (s, NH3(Ala)); 8.02 (s, NH(Phe(2Me))); 8.00 (d, J = 7.9, NH(Leu)); 7.25–
7.19, 7.10–7.09 (2m, 5 arom. H); 4.29–4.25 (m, CH(α)(Leu)); 3.93–3.91 (m, 
CH(α)(Ala)); 3.34 (s, PhCH2); 1.71–1.65 (m, CH(γ)(Leu), 1 H of CH2(Leu)); 
1.55–1.52 (m, 1 H of CH2(Leu)); 1.45 (s, Me(Phe(2Me))); 1.24 (d, J = 6.9, 
Me(Ala)); 0.92, 0.88 (2d, J = 6.4, 2 Me(Leu)). 13C-NMR ((D6)DMSO, 150 MHz): 
173.9 (s, CO(Leu)); 172.5 (s, CO(Phe(2Me))); 168.8 (s, CO(Ala)); 136.7 (s, arom. 
C); 130.1, 127.8, 126.4 (3d, 5 arom. CH); 60.2 (s, C(α)(Phe(2Me))); 50.8 (d, 
CH(α)(Leu)); 48.4 (d, CH(α)(Ala)); 39.8 (t, CH2(Leu)); 39.7 (t, PhCH2); 24.3 (d, 
CH(γ)(Leu)); 23.0 (q, Me(Phe(2Me))); 23.0, 21.1 (2q, 2 Me(Leu)); 17.2 (q, 
Me(Ala)). ESI-MS: 408 (5, [M – H + 2 Na]+), 386 (100, [M + Na]+), 364 (96, [M 
+ H]+), 293 (23, [M – Ala + H]+), 233 (24, [M – Leu]+), 205 (43, [M – Leu – 
CO]+), 134 (63). 
2(S)-({[({2-[({4-[(2(S)-Amino-3-methyl-1-oxobutyl)amino]tetrahydro-2H-
pyran-4-yl}carbonyl)amino]-1-
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oxoethyl}amino)cyclopentyl]carbonyl}amino)propanoic Acid (H–Val–Thp–Gly–
Acp–Ala–OH; 15). PAM resin (200 mg, 0.124 mmol) was treated as described in 
GP 1, 2, 3, 4, 5, 2, 3, 4, 5 and 6 to yield 15 (17.0 mg, 23%) as a colorless powder 
after prep. HPLC purification and lyophilization. HPLC-MS (method B): tR = 4.9 
min, m/z = 484 (100, [M + H]+). IR (KBr): 3337s, 3056s, 2971s, 2880m, 2642w, 
1720sh, 1670vs, 1534vs, 1455m, 1430w, 1400w, 1379w, 1333w, 1297m, 1240m, 
1202vs, 1141s, 1103m, 1027w, 961w, 935w, 840w, 800w, 722m. 1H-NMR 
((D6)DMSO, 600 MHz) (2 conformers): ca. 13.0–12.0 (br. s, COOH); 8.82 (s, 
NH(Thp)); 8.57 (w) (s, NH(Acp)); 8.11 (s, NH3(Val)); 8.04 (s, NH(Gly)); 7.73 (s) 
(s, NH(Acp)); 7.53 (w), 7.38 (s) (2d, J = 7.3, NH(Ala)); 4.26 (w), 4.14 (s) (2dq, J 
= 7.3, 7.3, CH(α)(Ala)); 3.77–3.71, 3.66–3.53, 3.47–3.43 (3m, CH(α)(Val), 
CH2(Gly), 2 CH2O(Thp)); 2.23–2.18, 2.14–2.07 (2m, CH(β)(Val), 1 H of 2 
CH2CH2O(Thp), 1 H of 2 CH2CH2C(α)(Acp)); 1.97–1.76 (m, 3 H of 2 
CH2CH2O(Thp), 3 H of 2 CH2CH2C(α)(Acp)); 1.69–1.56 (m, 2 
CH2CH2C(α)(Acp)); 1.27 (s), 1.24 (w) (2d, J = 7.3, Me(Ala)); 0.99 (s), 0.95 (s), 
0.94 (w, w) (3d, J = 6.9, Me(Val)). 13C-NMR ((D6)DMSO, 150 MHz) (2 
conformers): 173.9 (s, CO(Ala)); 173.3 (s, CO(Thp)); 173.2 (s, CO(Acp)); 168.7 
(s, CO(Gly)); 168.5 (s, CO(Val)); 66.4 (w), 65.9 (s) (2s, C(α)(Acp)); 62.5, 62.4 
(2t, 2 CH2O(Thp)); 57.6 (s), 57.6 (w) (2d, CH(α)(Val)); 56.9 (s, C(α)(Thp)); 47.7 
(s), 47.6 (w) (2d, CH(α)(Ala)); 43.2 (t, CH2(Gly)); 37.1, 35.2 (2t, 2 
CH2CH2C(α)(Acp)); 32.8, 30.1 (2t, 2 CH2CH2O(Thp)); 29.6 (s), 29.5 (w) (2d, 
CH(β)(Val)); 24.1 (s), 24.0 (s), 23.9 (w), 23.8 (w) (4t, 2 CH2CH2C(α)(Acp)); 18.6 
(s), 18.2 (w), 17.5 (w), 17.2 (s) (4q, 2 Me(Val)); 17.1 (w), 17.0 (s) (2q, Me(Ala)). 
ESI-MS: 484 (100, [M + H]+), 300 (20). 
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2(S)-{[4-({2(S)-[({4-[(2(S)-Amino-1-oxopropyl)amino]tetrahydro-2H-pyran-4-
yl}carbonyl)amino]-3-methyl-1-oxobutyl}amino)tetrahydro-2H-pyran-4-
yl]amino}-3-phenylpropanoic Acid (H–Ala–Thp–Val–Thp–Phe–OH; 16). PAM 
resin (200 mg, 0.124 mmol) was treated as described in GP 1, 2, 3, 4, 5, 2, 3, 4, 5 
and 6 to yield 16 (14.3 mg, 16%) as a colorless powder after prep. HPLC 
purification and lyophilization. HPLC-MS (method B): tR = 8.3 min, m/z = 590 
(100, [M + H]+), 425 (98, [M – Phe]+), 298 (48, [M – (Thp–Phe)]+). IR (KBr): 
3426s, 3306s, 3061s, 2967s, 2875m, 2620w, 1720s, 1671vs, 1533vs, 1469m, 
1444m, 1429m, 1393m, 1356w, 1302m, 1259m, 1245m, 1203vs, 1189sh, 1142s, 
1104s, 1029w, 968w, 946w, 917w, 838w, 800w, 722m, 702w. 1H-NMR 
((D6)DMSO, 600 MHz): ca. 13.0–12.5 (br. s, COOH); 8.52 (s, NH(Thp1)); 8.07 
(s, NH3(Ala)); 8.03 (s, NH(Thp2)); 7.45 (d, J = 7.9, NH(Phe)); 7.38 (d, J = 7.7, 
NH(Val)); 7.27–7.16 (m, 5 arom. H)); 4.43 (ddd, J = 7.9, 7.9, 5.9, CH(α)(Phe)); 
4.17 (dd, J = 7.3, 7.3, CH(α)(Val)); 3.99–3.97 (m, CH(α)(Ala)); 3.71–3.41 (m, 4 
CH2O(Thp)); 3.02 (dd, 2J = 13.8, J = 5.9, 1 H of CH2(Phe)); 2.95 (dd, 2J = 13.8, J 
= 7.5, 1 H of CH2(Phe)); 2.07–2.04 (m, CH(β)(Val)); 2.01–1.84 (m, 4 
CH2CH2O(Thp)); 1.39 (d, J = 7.0, Me(Ala)); 0.87, 0.82 (2d, J = 6.7, 2 Me(Val)). 
13C-NMR ((D6)DMSO, 150 MHz): 172.5 (s, 2 CO(Thp)); 172.4 (s, CO(Phe)); 
171.1 (s, CO(Val)); 169.7 (s, CO(Ala)); 137.2 (s, arom. C); 129.1, 128.1, 126.3 
(3d, 5 arom. CH); 62.4, 62.3, 62.3 (3t, 4 CH2O(Thp)); 58.4 (d, CH(α)(Val)); 57.1, 
56.9 (2s, 2 C(α)(Thp)); 53.3 (d, CH(α)(Phe)); 48.5 (d, CH(α)(Ala)); 36.9 (t, 
CH2(Phe)); 31.9, 31.7, 31.3, 31.1 (4t, 4 CH2CH2O(Thp)); 30.0 (d, CH(β)(Val)); 
19.5, 18.2 (2q, 2 Me(Val)); 17.1 (q, Me(Ala)). ESI-MS: 590 (100, [M + H]+), 425 
(27, [M – Phe]+). 




Acid (H–Ala–Aib–Val–Acp–Gly–Thp–Leu–OH; 17). PAM resin (200 mg, 0.124 
mmol) was treated as described in GP 1, 2, 3, 4, 5, 2, 3, 4, 5, 2, 3, 4, 5 and 6 to 
yield 17 (20.2 mg, 21%) as a colorless powder after prep. HPLC purification and 
lyophilization. For the ‘conventional’ coupling of Gly and Leu, the coupling was 
performed two times (1 × 2 h and 1 × overnight). HPLC-MS (method B): tR = 
11.9 min, m/z = 682 (100, [M + H]+). IR (KBr): 3314s, 3054m, 2962s, 2874m, 
1722sh, 1662vs, 1536vs, 1470m, 1448m, 1389m, 1368w, 1329w, 1295m, 1267m, 
1250sh, 1202s, 1172m, 1141m, 1107w, 1062w, 1029w, 977w, 947w, 929w, 851w, 
835w, 800w, 722w. 1H-NMR ((D6)DMSO, 600 MHz): ca. 12.6–12.1 (br. s, 
COOH); 8.69 (s, NH(Aib)); 8.49 (s, NH(Acp)); 8.23 (br. s, NH3(Ala)); 8.10 (t, J = 
5.6, NH(Gly)); 7.90 (d, J = 6.1, NH(Val)); 7.47 (s, NH(Thp)); 7.42 (d, J = 8.1, 
NH(Leu)); 4.23–4.19 (m, CH(α)(Leu)); 3.90–3.88 (m, CH(α)(Ala)); 3.79 (m, 
CH(α)(Val)); 3.68–3.64 (m, 3 H of 2 CH2O(Thp)); 3.60 (d, J = 5.6, CH2(Gly)); 
3.57–3.45 (m, 1 H of 2 CH2O(Thp)); 2.30–2.28 (m, 1 H of 2 CH2CH2C(α)(Acp)); 
2.19–2.16 (m, CH(β)(Val)); 2.09–2.02 (m, 2 H of 2 CH2CH2O(Thp)); 2.00–1.88 
(m, 1 H of 2 CH2CH2O(Thp), 3 H of 2 CH2CH2C(α)(Acp)); 1.84–1.80 (m, 1 H of 
2 CH2CH2O(Thp)); 1.72–1.60 (m, CH(γ)(Leu), 1 H of CH2(Leu), 4 H of 2 
CH2CH2C(α)(Acp)); 1.49–1.46 (m, 1 H of CH2(Leu)); 1.44, 1.40 (2s, 2 Me(Aib)); 
1.37 (d, J = 6.9, Me(Ala)); 0.88, 0.87 (2d, J = 6.7, 2 Me(Val)); 0.86, 0.82 (2d, J = 
6.4, 2 Me(Leu)). 13C-NMR ((D6)DMSO, 150 MHz): 175.0 (s, CO(Acp)); 174.7 (s, 
CO(Aib)); 173.8 (s, CO(Leu)); 173.1 (s, CO(Thp)); 172.4 (s, CO(Val)); 169.5 (s, 
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CO(Ala)); 168.9 (s, CO(Gly)); 66.1 (s, C(α)(Acp)); 62.4, 62.3 (2t, 2 CH2O(Thp)); 
60.1 (d, CH(α)(Val)); 57.1 (s, C(α)(Thp)); 56.4 (s, C(α)(Aib)); 50.3 (d, 
CH(α)(Leu)); 48.5 (d, CH(α)(Ala)); 44.1 (t, CH2(Gly)); 39.8 (t, CH2(Leu)); 36.9, 
35.7 (2t, 2 CH2CH2C(α)(Acp)); 32.7, 30.3 (2t, 2 CH2CH2O(Thp)); 28.3 (d, 
CH(β)(Val)); 25.4, 24.5 (2q, 2 Me(Aib)); 24.1, 24.1, 24.0 (d, 2t, CH(γ)(Leu), 2 
CH2CH2C(α)(Acp)); 23.0, 21.3 (2q, 2 Me(Leu)); 19.4, 19.3 (2q, 2 Me(Val)); 16.7 




methylpentanoic Acid (H–Ala–Aib–Val–Acp–Phe–Thp–Leu–OH; 18). PAM resin 
(200 mg, 0.124 mmol) was treated as described in GP 1, 2, 3, 4, 5, 2, 3, 4, 5, 2, 3, 
4, 5 and 6 to yield 18 (14.2 mg, 13%) as a colorless powder after prep. HPLC 
purification and lyophilization. HPLC-MS (method B): tR = 11.4 min, m/z = 772 
(100, [M + H]+). IR (KBr): 3431s, 3319s, 3062m, 3032m, 2962s, 2874m, 1726sh, 
1662vs, 1532vs, 1469m, 1454m, 1445m, 1389w, 1367w, 1326w, 1293sh, 1266m, 
1244m, 1202s, 1140s, 1108w, 1029w, 978w, 927w, 838w, 800w, 722w, 700w. 1H-
NMR ((D6)DMSO, 600 MHz): ca. 12.8–12.2 (br. s, COOH); 8.78 (br. s, 
NH(Aib)); 8.15 (br. s, NH3(Ala)); 8.04 (br. s, NH(Val), NH(Acp)); 7.72 (br. s, 
NH(Phe)); 7.61 (s, NH(Thp)); 7.26–7.24 (m, 2 arom. CH); 7.21–7.17 (m, 
NH(Leu), 3 arom. CH); 4.34–4.30 (m, CH(α)(Leu)); 4.23 (br. s, CH(α)(Phe)); 
3.87 (br. s, CH(α)(Ala)); 3.83–3.81 (m, CH(α)(Val)); 3.68–3.65 (m, 3 H of 2 
CH2O(Thp)); 3.34–3.31 (m, 1 H of CH2(Phe)); 3.26–3.22 (m, 1 H of 2 
CH2O(Thp)); 2.92–2.87 (m, 1 H of CH2(Phe)); 2.16–2.15 (m, 2 H of 2 
page 21 / 39 
CH2CH2O(Thp)); 2.08–2.04 (m, CH(β)(Val), 1 H of 4 CH2(Acp)); 1.99–1.94 (m, 
1 H of 2 CH2CH2O(Thp), 1 H of 4 CH2(Acp)); 1.79–1.71 (m, CH(γ)(Leu), 1 H of 
2 CH2CH2O(Thp), 2 H of 4 CH2(Acp)); 1.69–1.58 (m, 1 H of CH2(Leu), 4 H of 4 
CH2(Acp)); 1.49–1.44 (m, 1 H of CH2(Leu)); 1.49 (s, 1 Me of 2 Me(Aib)); 1.37 
(d, J = 6.9, Me(Ala)); 1.36 (s, 1 Me of 2 Me(Aib)); 0.91 (d, J = 6.8, 1 Me of 2 
Me(Val)); 0.88 (d, J = 6.7, 1 Me of 2 Me(Leu)); 0.85 (d, J = 6.7, 1 Me of 2 
Me(Val), 1 Me of 2 Me(Leu)). 13C-NMR ((D6)DMSO, 150 MHz): 175.9 (s, 
CO(Aib)); 174.2 (s, CO(Acp)); 173.9 (s, CO(Leu)); 172.9 (s, CO(Thp)); 172.6 (s, 
CO(Val)); 170.3 (s, CO(Phe)); 169.4 (s, CO(Ala)); 138.4 (s, arom. C); 129.0, 
128.2, 126.1 (3d, 5 arom. CH); 66.3 (s, C(α)(Acp)); 62.5, 62.3 (2t, 2 CH2O(Thp)); 
60.8 (d, CH(α)(Val)); 57.1 (s, C(α)(Thp)); 56.2 (s, C(α)(Aib)); 54.9 (d, 
CH(α)(Phe)); 49.8 (d, CH(α)(Leu)); 48.4 (d, CH(α)(Ala)); 40.2 (t, CH2(Leu)); 
36.1, 36.0 (2t, 2 CH2CH2C(α)(Acp)); 35.5 (t, CH2(Phe)); 33.7, 28.7 (2t, 2 
CH2CH2O(Thp));  28.5 (d, CH(β)(Val)); 25.3, 24.3 (2q, 2 Me(Aib)); 24.1, 24.0 
(2t, 2 CH2CH2C(α)(Acp)); 23.7 (d, CH(γ)(Leu)); 23.1, 21.1 (2q, 2 Me(Leu)); 
19.3, 18.4 (2q, 2 Me(Val)); 16.7 (q, Me(Ala)). ESI-MS: 772 (100, [M + H]+). 
2-({2-[(2-Amino-2-methyl-1-oxopropyl)amino]-2-methyl-1-oxopropyl}amino)-
2-methylpropanoic Acid (H–Aib–Aib–Aib–OH; 19). PAM resin (200 mg, 0.124 
mmol) was treated as described in GP 1, 2, 3, 4, 3 and 6 to yield 19 (15.9 mg, 
33%) as a colorless powder after prep. HPLC purification and lyophilization. 
HPLC-MS (method A): tR = 1.3 min, m/z = 274 (100, [M + H]+). IR (KBr): 
3508m, 3359s, 3262m, 3119s, 3064s, 2994s, 2947s, 2604w, 1719vs, 1667vs, 
1519vs, 1472m, 1440m, 1406w, 1390w, 1367w, 1258s, 1203vs, 1179vs, 1144vs, 
947w, 925w, 911w, 839w, 801w, 773w, 723m. 1H-NMR ((D6)DMSO, 300 MHz): 
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ca. 9.0–7.0 (br. s, NH3); 8.00, 7.38 (2s, 2 NH); 1.49, 1.41, 1.38 (3s, 6 Me). 13C-
NMR ((D6)DMSO, 75 MHz): 175.8, 172.6, 170.7 (3s, 3 CO); 56.6, 56.5, 55.2 (3s, 
3 C(α)); 24.5, 24.4, 23.3 (3q, 6 Me). ESI-MS: 274 (100, [M + H]+), 170 (4, [M – 
Aib]+). 
2-({2-[(2(S)-Amino-1-oxopropyl)amino]-2-methyl-1-oxopropyl}amino)-2-
methylpropanoic Acid (H–Ala–Aib–Aib–OH; 20). PAM resin (200 mg, 0.124 
mmol) was treated as described in GP 1, 2, 3, 4, 3 and 6 to yield 20 (19.0 mg, 
41%) as a colorless powder after prep. HPLC purification and lyophilization. 
HPLC-MS (method A): tR = 1.3 min, m/z = 260 (100, [M + H]+). IR (KBr): 3284s, 
3072s, 2993s, 2945s, 2631w, 1726vs, 1673vs, 1530vs, 1471m, 1458m, 1441m, 
1389m, 1368m, 1264s, 1204vs, 1141vs, 1005w, 930w, 880w, 838m, 801m, 768w, 
723m. 1H-NMR ((D6)DMSO, 600 MHz): ca. 8.8–7.5 (br. s, NH3(Ala));  8.38 (s, 
NH(Aib2)); 7.46 (s, NH(Aib3)); 3.85 (q, J = 6.9, CH(α)(Ala)); 1.41–1.34 (m, 4 
Me(Aib), Me(Ala)). 13C-NMR ((D6)DMSO, 150 MHz): 175.7 (s, CO(Aib3)); 
172.5 (s, CO(Aib2)); 168.9 (s, CO(Ala)); 56.3 (s, C(α)(Aib2)); 55.2 (s, 
C(α)(Aib3)); 48.3 (d, CH(α)(Ala)); 24.8, 24.5, 24.5, 24.4 (4q, 4 Me(Aib)); 17.1 
(q, Me(Ala)). ESI-MS: 519 (36, [2M + H]+), 260 (100, [M + H]+). 
2-{[2-({2-[(2(S)-Amino-1-oxopropyl)amino]-2-methyl-1-oxopropyl}amino)-2-
methyl-1-oxopropyl]amino}-2-methylpropanoic Acid (H–Ala–Aib–Aib–Aib–OH; 
21). PAM resin (200 mg, 0.124 mmol) was treated as described in GP 1, 2, 3, 4, 3, 
4, 3 and 6 to yield 21 (7 mg, 12%) as a colorless powder after prep. HPLC 
purification and lyophilization. Additional 20 was isolated as a colorless powder 
(16 mg, 35%). HPLC-MS (method A): tR = 1.5 min, m/z = 345 (100, [M + H]+). 
IR(KBr): 3432vs, 3262vs, 3120vs, 2992vs, 2939s, 1670vs, 1543vs, 1535vs, 
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1469s, 1460s, 1399vs, 1367m, 1261m, 1204vs, 1182s, 1141s, 1089w, 1048w, 
1025w, 1005w, 722w. 1H-NMR ((D6)DMSO, 600 MHz): ca. 12.2–11.8 (br. s, 
COOH); 8.61 (s, NH(Aib)); 8.04 (br. s, NH3(Ala)); 7.44, 7.31 (2s, 2 NH(Aib)); 
3.87 (br. s, CH(α)(Ala)); 1.39–1.34 (m, 6 Me(Aib), Me(Ala)). 13C-NMR 
((D6)DMSO, 150 MHz): 174.4, 172.2, 171.1, 168.1 (4s, 4 CO); 55.2, 54.6, 53.8 
(3s, 3 C(α)(Aib)); 47.1 (d, CH(α)(Ala)); 23.9, 23.6, 23.5, 23.3, 23.3, 23.2 (6q, 6 
Me(Aib)); 15.8 (q, Me(Ala)). ESI-MS: 345 (100, [M + H]+). 
2-[(2-{[2-({2(S)-[(2(S)-Amino-1-oxopropyl)amino]-3-methyl-1-
oxobutyl}amino)-2-methyl-1-oxopropyl]amino}-2-methyl-1-oxopropyl)amino]-2-
methylpropanoic Acid (H–Ala–Val–Aib–Aib–Aib–OH; 22). PAM resin (200 mg, 
0.124 mmol) was treated as described in GP 1, 2, 5, 2, 3, 4, 3, 4, 3 and 6 to yield 
22 (11.0 mg, 16%) as a colorless powder after prep. HPLC purification and 
lyophilization. HPLC-MS (method A): tR = 8.4 min, m/z = 444 (100, [M + H]+). 
IR (KBr): 3431s, 3304s, 3063s, 2987s, 2942s, 2883m, 2629w, 1720sh, 1667vs, 
1534vs, 1469m, 1389m, 1366m, 1203vs, 1181vs, 1140s, 1010w, 935w, 837w, 
800w, 776w, 722m. 1H-NMR ((D6)DMSO, 600 MHz): ca. 9.5–7.5 (br. s, 
NH3(Ala));  8.40 (s, NH(Aib3)); 8.33 (d, J = 7.6, NH(Val)); 7.34 (s, NH(Aib5)); 
7.13 (s, NH(Aib4)); 4.11 (dd, J = 7.2, 7.2, CH(α)(Val)); 3.95 (q, J = 6.9, 
CH(α)(Ala)); 2.05 (dsept., J = 6.8, 6.8, CH(β)(Val)); 1.33–1.29 (m, 6 Me(Aib), 
Me(Ala)); 0.93, 0.91 (2d, J = 7.0, 2 Me(Val)). 13C-NMR ((D6)DMSO, 150 MHz): 
175.6 (s, CO(Aib5)); 173.3 (s, CO(Aib4)); 172.6 (s, CO(Aib3)); 170.9 (s, 
CO(Val)); 169.8 (s, CO(Ala)); 58.3 (d, CH(α)(Val)); 56.1 (s, C(α)(Aib3)); 55.7 (s, 
C(α)(Aib4)); 54.8 (s, C(α)(Aib5)); 47.9 (d, CH(α)(Ala)); 30.0 (d, CH(β)(Val)); 
25.0 (q, 1 Me of 2 Me(Aib3)); 24.9 (q, 1 Me of 2 Me(Aib4)); 24.8, 24.5 (2q, 2 
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Me(Aib5)); 24.4 (q, 1 Me of 2 Me(Aib4)); 24.2 (q, 1 Me of 2 Me(Aib3)); 19.2, 




Leu–OH; 23). PAM resin (200 mg, 0.124 mmol) was treated as described in GP 1, 
2, 5, 2, 5, 2, 3, 4, 3, 4, 5 and 6 to yield 23 (5.3 mg, 6%) as a colorless powder after 
prep. HPLC purification and lyophilization. HPLC-MS (method B): tR = 11.1 min, 
m/z = 619 (100, [M + H]+). IR (KBr): 3421s, 3312s, 3065m, 3034m, 2964s, 
2939m, 2876m, 1668vs, 1534vs, 1468m, 1460m, 1442m, 1388m, 1367w, 1203vs, 
1190sh, 1140s, 837w, 800w, 745w, 722w, 700w. 1H-NMR ((D6)DMSO, 600 
MHz): ca. 12.4–12.1 (br. s, COOH); 8.32 (d, J = 5.7, NH(Phe)); 8.26 (d, J = 8.6, 
NH(Val)); 8.19 (s, NH(Aib4)); 8.04 (br. s, NH3(Ala)); 7.32 (s, NH(Aib5)); 7.30–
7.18 (m, 5 arom. H, NH(Leu)); 4.41 (ddd, J = 8.1, 6.3, 6.3, CH(α)(Phe)); 4.15 (dd, 
J = 8.2, 8.2, CH(α)(Val)); 4.13–4.10 (m, CH(α)(Leu)); 3.93–3.90 (m, 
CH(α)(Ala)); 2.95 (dd, J = 13.9, 6.5, 1 H of CH2(Phe)); 2.88 (dd, J = 13.9, 8.5, 1 
H of CH2(Phe)); 1.92 (dsept., J = 7.0, 7.0, CH(β)(Val)); 1.72–1.63 (m, 
CH(γ)(Leu), 1 H of CH2(Leu)); 1.47–1.42 (m, 1 H of CH2(Leu)); 1.34, 1.31 (2s, 2 
Me(Aib5)); 1.26 (d, J = 7.0, Me(Ala)); 1.19, 1.12 (2s, 2 Me(Aib4)); 0.90 (d, J = 
6.7, 1 Me of 2 Me(Val)); 0.87 (d, J = 6.5, 1 Me of 2 Me(Leu)); 0.84 (d, J = 6.7, 1 
Me of 2 Me(Val)); 0.81 (d, J = 6.5, 1 Me of 2 Me(Leu)). 13C-NMR ((D6)DMSO, 
150 MHz): 174.1 (s, CO(Aib5)); 173.8 (s, CO(Leu)); 172.6 (s, CO(Aib4)); 171.0 
(s, CO(Phe)); 170.7 (s, CO(Val)); 169.2 (s, CO(Ala)); 137.0 (s, arom. C); 129.1, 
127.9, 126.2 (3d, 5 arom. CH); 57.8 (d, CH(α)(Val)); 55.9 (s, C (α)(Aib4)); 55.6 
page 25 / 39 
(s, C(α)(Aib5)); 54.5 (d, CH(α)(Phe)); 50.3 (d, CH(α)(Leu)); 47.8 (d, 
CH(α)(Ala)); 39.6 (t, CH2(Leu)); 36.9 (t, CH2(Phe)); 30.3 (d, CH(β)(Val)); 25.9 
(q, 1 Me of 2 Me(Aib5)); 25.8 (q, 1 Me of 2 Me(Aib4)); 23.8 (d, CH(γ)(Leu)); 23.5 
(q, 1 Me of 2 Me(Aib5)); 23.4 (q, 1 Me of 2 Me(Aib4)); 23.0, 21.0 (2q, 2 
Me(Leu)); 19.2, 18.5 (2q, 2 Me(Val)); 17.3 (q, Me(Ala)). ESI-MS: 619 (100, [M + 




Acid (H–Ala–Val–Phe–Aib–Aib–Aib–Leu–OH; 24). PAM resin (200 mg, 0.124 
mmol) was treated as described in GP 1, 2, 5, 2, 5, 2, 3, 4, 3, 4, 3, 4, 5 and 6 to 
yield 24 (8.6 mg, 9%) as a colorless powder after prep. HPLC purification and 
lyophilization. HPLC-MS (method B): tR = 11.1 min, m/z = 704 (100, [M + H]+). 
IR (KBr): 3422s, 3307s, 3065s, 3033s, 2964s, 2941s, 2875m, 1667vs, 1532vs, 
1468m, 1458m, 1442m, 1387m, 1366m, 1276m, 1203vs, 1188s, 1140s, 945w, 
923w, 837w, 800w, 722w, 700w. 1H-NMR ((D6)DMSO, 600 MHz): ca. 12.3–12.1 
(br. s, COOH); 8.44 (s, NH(Aib4)); 8.42 (d, J = 4.9, NH(Phe)); 8.26 (d, J = 8.6, 
NH(Val)); 8.04 (br. s, NH3(Ala)); 7.53, 7.41 (2s, NH(Aib5), NH(Aib6)); 7.40 (d, J 
= 7.9, NH(Leu)); 7.28–7.20 (m, 5 arom. H); 4.41 (td, J = 7.6, 5.1, CH(α)(Phe)); 
4.20 (dd, J =8.1, 8.1, CH(α)(Val)); 4.18–4.14 (m, CH(α)(Leu)); 3.91 (br. s, 
CH(α)(Ala)); 2.96–2.89 (m, CH2(Phe)); 1.93 (dsept., J = 7.0, 7.0, CH(β)(Val)); 
1.78–1.75 (m, CH(γ)(Leu)); 1.73–1.69, 1.44–1.39 (2m, CH2(Leu)); 1.34, 1.33, 
1.30, 1.26 (4s, 4 Me of 6 Me(Aib)); 1.26 (d, J = 6.5, Me(Ala)); 1.20, 1.14 (2s, 2 
Me of 6 Me(Aib)); 0.94, 0.88 (2d, J = 6.8, 2 Me(Val)); 0.83, 0.81 (2d, J = 6.6, 2 
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Me(Leu)). 13C-NMR ((D6)DMSO, 150 MHz): 174.3, 174.1 (2s, 2 CO of 3 
CO(Aib)); 174.0 (s, CO(Leu)); 173.0 (s, 1 CO of 3 CO(Aib)); 171.7 (s, CO(Phe)); 
170.8 (s, CO(Val)); 169.2 (s, CO(Ala)); 136.8 (s, arom. C); 129.2, 127.9, 126.3 
(3d, 5 arom. CH); 57.6 (d, CH(α)(Val)); 56.1, 55.8, 55.7 (3s, 3 C(α)(Aib)); 54.5 
(d, CH(α)(Phe)); 50.2 (d, CH(α)(Leu)); 47.8 (d, CH(α)(Ala)); 39.8 (t, CH2(Leu)); 
36.7 (t, CH2(Phe)); 30.3 (d, CH(β)(Val)); 26.7, 26.1, 25.9 (3q, 3 Me of 6 
Me(Aib)); 23.6 (d, CH(γ)(Leu)); 23.4, 23.2 (2q, 2 Me of 6 Me(Aib)); 23.0 (q, 1 
Me of 2 Me(Leu)); 22.9 (q, 1 Me of 6 Me(Aib)); 21.0 (q, 1 Me of 2 Me(Leu)); 
19.2, 18.5 (2q, 2 Me(Val)); 17.3 (q, Me(Ala)). ESI-MS: 704 (100, [M + H]+), 573 
(21, [M – Leu]+). 
5. Derivatization of (S,S,S)-13 and (S,R,S)-13. 2(S)-{[2(S)-({2(S)-[4-
Bromobenzoyl)amino]-1-oxopropyl}amino)-2-benzyl-1-oxopropyl]amino}-4-
methylpentanoic Acid (p-BrBz–Ala–Phe(2Me)–Leu–OH; (S,S,S)-14) and 2(S)-
{[2(R)-({2(S)-[4-Bromobenzoyl)amino]-1-oxopropyl}amino)-2-benzyl-1-
oxopropyl]amino}-4-methylpentanoic Acid (p-BrBz–Ala–Phe(2Me)–Leu–OH; 
(S,R,S)-14). At 0° 4-bromobenzoylchloride (8 mg, 0.036 mmol) was added to a 
mixture of (S,S,S)-13 (ca. 12 mg, 0.025 mmol) and K2CO3 (12 mg, 0.087 mmol) 
and (S,R,S)-13 (ca. 12 mg, 0.025 mmol) and K2CO3 (12 mg, 0.087 mmol), resp., 
in acetone (5 ml) and H2O (1 ml), then stirred at r.t. for 2 h. The org. solvent was 
removed under reduced pressure and the residue acidified with diluted aq. HCl. 
The resulting precipitation was filtered and purified by prep. TLC (CH2Cl2/MeOH 
10:1; 2 × dev.) yielding colorless powders (8 mg (59%) and 6 mg (44%), resp.). 
Suitable crystals for the X-ray crystal-structure determination of (S,S,S)-14 were 
grown from MeOH/CHCl3/Et2O. Data of (S,S,S)-14. ESI-MS: 593 (10), 592 (30, 
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[M(81Br) – H + 2 Na]+), 591 (10), 590 (33, [M(79Br) – H + 2 Na]+), 571 (42), 570 
(100, [M(81Br) + Na]+), 569 (34), 568 (86, [M(79Br) + Na]+). 
Data of (S,R,S)-14. ESI-MS: 593 (5), 592 (11, [M(81Br) – H + 2 Na]+), 591 (5), 
590 (11, [M(79Br) – H + 2 Na]+), 571 (29), 570 (100, [M(81Br) + Na]+), 569 (26), 
568 (72, [M(79Br) + Na]+). 
6. X-Ray Crystal-Structure Determination of (S,S,S)-14, (see Table 3 and Fig. 
1)2). A crystal of C26H32BrN3O5·MeOH, obtained from MeOH/CHCl3/Et2O, was 
used for a low-temperature X-ray structure determination. All measurements were 
made on a Nonius KappaCCD area-detector diffractometer [27] using graphite-
monochromated MoKα radiation (λ 0.71073 Å) and an Oxford Cryosystems 
Cryostream 700 cooler. The data collection and refinement parameters are given 
in Table 3 and a view of the molecule is shown in the Fig. 
Data reduction was performed with HKL Denzo and Scalepack [28]. The 
intensities were corrected for Lorentz and polarization effects, and an absorption 
correction based on the multi-scan method [29] was applied. Equivalent 




The structure was solved by direct methods using SHELXS97 [30], which 
revealed the positions of all non-H-atoms. There are two symmetry-independent 
                                                 
2) CCDC-287054 contains the supplementary crystallographic data for this 
paper. These data can be obtained free of charge from the Cambridge 
Crystallographic Data Center via 
http://www.ccdc.cam.ac.uk/data_request/cif. 
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peptide and two MeOH molecules in the asymmetric unit. The atomic coordinates 
were tested carefully for a relationship from a higher symmetry space group by 
using the program PLATON [31], but none could be found. The non-hydrogen 
atoms were refined anisotropically. The hydroxy H-atoms of the peptide and 
MeOH molecules were placed in the positions indicated by a difference electron 
density map and their positions were allowed to refine together with individual 
isotropic displacement parameters. All remaining H-atoms were placed in 
geometrically calculated positions and refined using a riding model where each H-
atom was assigned a fixed isotropic displacement parameter with a value equal to 
1.2Ueq of its parent C-atom (1.5Ueq for the methyl groups). The refinement of the 
structure was carried out on F2 using full-matrix least-squares procedures, which 
minimised the function Σw(Fo2 – Fc2)2. A correction for secondary extinction was 
not applied. Eleven reflections, whose intensities were considered to be extreme 
outliers, were omitted from the final refinement. Refinement of the absolute 
structure parameter [32] yielded a value of 0.00(1), which confidently confirms 
that the refined model represents the true enantiomorph. Neutral atom scattering 
factors for non-H-atoms were taken from [33a], and the scattering factors for H-
atoms were taken from [34]. Anomalous dispersion effects were included in Fc 
[35]; the values for f ' and f " were those of [33b]. The values of the mass 
attenuation coefficients are those of [33c]. All calculations were performed using 
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Tables 
 
Table 1. Synthesized peptides containing Aib, Acp, Thp and Phe(2Me) residues. 
 
Sequence Yield [%] a) 
H–Ala–Acp–Phe–OH (11a) 37 
H–Ala–Thp–Phe–OH (11b) 38 
H–Ala–Phe(2Me)–Leu–OH (13) 49 
H–Val–Thp–Gly–Acp–Ala–OH (15) 23 
H–Ala–Thp–Val–Thp–Phe–OH (16) 16 
H–Ala–Aib–Val–Acp–Gly–Thp–Leu–OH (17) 21 
H–Ala–Aib–Val–Acp–Phe–Thp–Leu–OH (18) 13 
 
a) Yield of product isolated after HPLC purification, based on resin loading. 
 
Table 2. Synthesized peptides containing poly-Aib motifs. 
 
Sequence Yield [%] a) 
H–Aib–Aib–Aib–OH (19) 33 
H–Ala–Aib–Aib–OH (20) 41 
H–Ala–Aib–Aib–Aib–OH (21) 12 b) 
H–Ala–Val–Aib–Aib–Aib–OH (22) 16 
H–Ala–Val–Phe–Aib–Aib–Leu–OH (23) 6 
H–Ala–Val–Phe–Aib–Aib– Aib–Leu–OH (24) 9 
 
a) Yield of product isolated after HPLC purification, based on resin loading. 
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Table 3. Crystallographic data of compound (S,S,S)-14. 
 
Crystallized from MeOH/CHCl3/Et2O  
Empirical formula C27H36BrN3O6  
Formula weight [g mol–1] 578.50  
Crystal color, habit colorless, plate  
Crystal dimensions [mm] 0.03 × 0.15 × 0.22  
Temperature [K] 160(1)  
Crystal system monoclinic  
Space group P21  
Z 4  
Reflections for cell determination 84590  
2θ range for cell determination [°] 4 – 50  
Unit cell parameters a [Å] 15.2292(6)  
 b [Å] 10.1998(4)  
 c [Å] 18.6076(8)  
 β [°] 91.810(2)  
 V [Å3] 2889.0(2)  
Dx [g cm–3] 1.330  
µ(MoKα) [mm–1] 1.470  
Scan type ω  
2θ (max) [°] 50  
Transmission factors (min; max) 0.737; 0.982  
Total reflections measured 43528  
Symmetry independent reflections 10174  
Reflections with I > 2σ (I) 6247  
Reflections used in refinement 10163  
Parameters refined; restraints 693; 1  
Final R(F)  [I > 2σ (I) reflections] 0.0646  
 wR(F2)  (all data) 0.1480  
Weights:             w = [σ 2(Fo2) + (0.0518P)2 + 1.5382P]-1 where P = (Fo2 + 2Fc2) / 
3 
Goodness of fit 1.036  
Final ∆ max /σ 0.001  
∆ρ (max; min) [e Å–3] 0.49; -0.44  
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Legends 
 
Table 1. Synthesized peptides containing Aib, Acp, Thp and Phe(2Me) residues. 
Table 2. Synthesized peptides containing poly-Aib motifs. 
Table 3. Crystallographic data of compound (S,S,S)-14. 
Scheme 1. DIPEA = N,N-diisopropylethylamine; HOBt: 1-hydroxybenzotriazole; 
PyBOP = (1H-benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate; TFA = trifluoroacetic acid; TIPS = triisopropylsilane. 
Fig. 1. ORTEP Plot [17] of the molecular structure of one of the two symmetry-
independent molecules of (S,S,S)-14 (50% probability ellipsoids; arbitrary 
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Formula collections 
 















































































5  R = N(Me)Ph
1
6  R = OH
1) COCl2 (1.9 M in PhMe), THF
2) H-Ala-OtBu · HCl, DIPEA, CH2Cl2
3  R = OtBu
1










1. H–Phe–OtBu . HCl, HOBt,







































































7 steps, 49% yield
(S,S,S)-14 (S,R,S)-14
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Scheme for Table of Contents 
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